Kaptopril Krka

Captopril, the active ingredient in Kaptopril Krka, is an ACE inhibitor presented as a tablet for oral use. It lowers blood pressure and is used to manage hypertension, heart failure, post‑myocardial infarction and diabetic nephropathy in adult patients.

GNH USA supplies Kaptopril Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Captopril belongs to the ACE inhibitor class and acts on the renin‑angiotensin‑aldosterone system to control cardiovascular conditions. - Hypertension: reduces systolic and diastolic pressure, decreasing risk of stroke and heart attack. - Heart failure: improves cardiac output and symptoms by lowering afterload. - Post‑myocardial infarction: limits ventricular remodeling and reduces mortality. - Diabetic nephropathy: slows progression of renal impairment by lowering intraglomerular pressure.

Captopril may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness or light‑headedness, especially after standing. - Headache. - Fatigue or weakness. - Taste disturbances, often metallic. - Mild hypotension.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway. - Neutropenia or leukopenia. - Severe skin reactions such as Stevens‑Johnson syndrome. - Hepatic injury with elevated enzymes. - Acute renal failure, particularly in volume‑depleted patients. - Anaphylactic reactions.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events. - Monitor blood pressure: adjust dose if hypotension occurs. - Assess renal function: dose may need adjustment in impairment. - Avoid use in pregnancy: category D, risk to fetus. - Use cautiously with potassium‑sparing diuretics or supplements to prevent hyperkalaemia. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Captopril can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal dysfunction. - Lithium: may raise lithium levels, causing toxicity. - Potassium supplements or other ACE inhibitors/ARBs: risk of severe hyperkalaemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Loop or thiazide diuretics: can enhance hypotensive response. - Beta‑blockers: additive blood‑pressure lowering effect, requiring careful titration.